ESC events in Asia tackle management of diabetes and cardiovascular disease

October 30, 2009

With the rapidly increasing problem of cardiovascular (CVD) disease in Asia Pacific (AP), there is an urgency to raise awareness of risk factors. The European Society of Cardiology (ESC) is addressing the need to develop and adopt an integrated approach to CVD management, through important events organised in the region.

CVD has become more prevalent in India and China than in all of the economically-developed countries in the world combined.1 The trend is particularly evident in the younger population; data shows a 15% increase in prescriptions of agents to manage cardiovascular risk factors in young adults.2 One of the greatest concerns is the development of type 2 diabetes, with up to 50% of deaths in diabetes patients related to CVD.3 Estimates predict diabetes will rise in South East Asia by more than 33% by 2025 - the highest percentage increase around the globe.4

Furthermore, there is evidence to show that CV risk factors may have greater impact in Asian populations; for the same levels of systolic blood pressure Asian patients have a greater risk of developing coronary heart disease and stroke compared with Caucasians.5 The burden of CVD is predicted to severely impact healthcare systems - the WHO estimates that China is likely to lose US $558 in national income as a result of rising heart disease, stroke and diabetes.4

Following on from successful events organised last year, a second Joint Scientific Forum, organised by the ESC and the European Association for the Study of Diabetes (EASD), will be held on 27 November at three venues across China - Beijing, Shanghai and Guangzhou. The theme is the Optimal Management for Diabetes, with talks given for an audience of clinicians who treat diabetes and cardiology patients. Subjects to be covered include long-term efficacy for current treatment, early intervention and combination treatment for maximum benefit, Hyperglycemia and CVD, and Diabetic cardiopathy.

Following last year's inaugural event, a second ESC Asia Cardiovascular Symposium was held in Beijing on 12 September. The one-day programme provided an opportunity for leading physicians from Asian countries to examine CVD risk factors and discuss management of an increasing precedence of the disease - attributed to westernisation of diet and lifestyle. The first ESC Asia Cardiovascular Symposium in Shanghai in September 2008 aimed to raise awareness of the growing burden of CVD in the AP region, and the need for screening and risk assessment tools for early detection and intervention.

The second symposium set out to take the next step by: The September symposium was co-chaired by three experts in the fields of cardiovascular medicine: Professor Lars Rydén (Sweden) representing the ESC, Professor Lim Yean Teng (Singapore) and Professor Yong Huo (China). For the attending delegates, who came from all over AP and represented a number of specialties, the programme provided an opportunity to look at a multifactorial approach to CVD risk management. Using patient case studies, speakers demonstrated how lifestyle modification often has to be supplemented by pharmacotherapy. Panel discussions raised important issues such as the need to proactively manage patients with atrial fibrillation, who are at increased risk of stroke. There was agreement among the disciplines that intervention per se should be based on total cardiovascular risk, but that each of the contributing risk factors needs to be managed with appropriate, evidence based agents. However, putting this into practice remains a challenge for physicians across the globe, highlighting the need for greater awareness and education regarding the benefits of timely implementation, and for surveys on actual practice.
-end-
References
1. WHO Global Report, WHO 2005.
2. Liberman JN, et al. Archives of Pediatric and Adolescent Medicine 2009:163;357-64
3. Diabetes Fact Sheet No. 312. WHO Geneva 2008. www.who.int/mediacentre/factsheets/fs312/en/index.html
4. IDF 2008. www.idf.org
5. Perkovic V, et al. Hypertension 2007;50;991-7

Contact:

Education Department
European Society of Cardiology
Tel: +33 (0) 4 92 94 86 37
Fax: +33 (0) 4 89 872012
Email: education@escardio.org

ESC Press Office
European Society of Cardiology (for information on the ESC and independent comment):
Tel: +33 (0) 4 92 94 86 27
Fax: +33 (0) 4 92 948669
Email: press@escardio.org

Ms. Lisa Cheng, Project Manager for the 2nd ESC Asia Cardiovascular Symposium
EMD Asia Scientific Communication Ltd.
Unit 4002B, 40th Floor , Metroplaza Tower 2
223 Hing Fong Road, Kwai Fong, Hong Kong
Tel: +852 3690 1213
Fax: +852 3690 1219
Email: lisa.cheng@emd-asia.com

REFERENCES

The European Society of Cardiology (ESC) represents more than 62,000 cardiology professionals across Europe and the Mediterranean. Its mission is to reduce the burden of cardiovascular disease in Europe.

European Society of Cardiology

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.